

Long-Acting Reversible Contraception

Courtney C. Baker, MD, MPH, and Mitchell D. Creinin, MD

Long-acting reversible contraceptive (LARC) methods are effective options for pregnancy prevention. Currently available products in the United States include an etonogestrel implant, a copper intrauterine device (IUD), and several levonorgestrel IUDs. With increasing prevalence and duration of use, our understanding of efficacy, risks, and benefits has evolved. In addition to a brief discussion on nomenclature and LARC use within a framework of bodily autonomy and reproductive justice, this review covers clinical challenges with placement and removal, evidence-based duration of use, and how to mitigate side effects. Although all obstetrician-gynecologists as well as primary care clinicians can safely provide LARCs, complex family planning specialists are an expert referral source for challenging cases and evidence-based care as contraceptive technology continues to develop.

(*Obstet Gynecol* 2022;140:883–97)

DOI: 10.1097/AOG.0000000000004967

Long-acting reversible contraceptive (LARC) methods are effective options that can be used by most patients seeking to prevent pregnancy. Long-acting reversible contraceptives prevent pregnancy for 1 year or longer with a single administration.¹ Currently marketed LARC products include implants, nonhormonal intrauterine devices (IUDs), and hormonal IUDs.

Long-acting reversible contraceptive use has been increasing since the early 2000s, with 18% of contraceptors reporting use of an IUD (14%) or implant (4%) in 2016.² Unintended pregnancy, although declining in incidence, continues to account for 45% of U.S. pregnancies, and rates remain disproportionately high

among people with less financial means.³ Although multiple factors contribute to unintended pregnancy rates, increasing LARC use correlates with declining rates and is likely a contributing factor.^{4,5}

Currently available LARCs in the United States are described in Table 1. Given the expansion of available IUD products, consistent and clear IUD nomenclature is critical. In this review, we will refer to IUDs according to Society of Family Planning guidelines.⁶ Per these recommendations, IUD categories should be referred to as nonhormonal and hormonal. The specific types of IUDs should be denoted as copper or hormone-type (eg, levonorgestrel), followed by the dose.

In addition, we would like to contextualize LARC use within a lens of bodily autonomy and reproductive justice. Over the past decade, there has been significant research and funding pertaining to LARCs, with the intention of increasing education and access for people desiring pregnancy prevention. As a community reflecting on our efforts to provide tools for reproductive health goals, it is vital that we approach contraception, especially methods that require a clinician for initiation and discontinuation, within the framework of our patient's preferences and goals. Long-acting reversible contraceptives, although an effective choice, are not the best choice for everyone. In addition, we must remember the history of racism, eugenics, and coercion in contraceptive technology when we consider how we discuss and promote LARC use.⁷

From the Department of Obstetrics and Gynecology, University of California, Davis, Sacramento, California.

This article discusses Liletta, which is scheduled for approval for 8-year use by the U.S. Food and Drug Administration in November 2022.

Each author has confirmed compliance with the journal's requirements for authorship.

Corresponding author: Mitchell D. Creinin, MD, University of California, Davis, Sacramento, CA; email: mdcreinin@ucdavis.edu.

Financial Disclosure

Mitchell D. Creinin has received speaking honoraria from Gedeon Richter and Mayne, serves on an Advisory Boards for Evofem, Fuji Pharma, Mayne, Merck, Searchlight, and TherapeuticsMD, and is a consultant for Estetra SRL, Libbs, Mayne, and Medicines360. The Department of Obstetrics and Gynecology, University of California, Davis, receives contraceptive research funding for Dr. Creinin from Chemo Research SL, Evofem, HRA Pharma, Medicines360, Merck, and Sebela. Courtney Baker did not report any potential conflicts of interest.

© 2022 by the American College of Obstetricians and Gynecologists. Published by Wolters Kluwer Health, Inc. All rights reserved.

ISSN: 0029-7844/22



Table 1. Long-Acting Reversible Contraceptive Methods Currently Available in the United States and First-Year Efficacy

Device	Brand Name(s)	% of Users Experiencing Pregnancy in the 1st Year ¹	
		Perfect Use	Typical Use
Etonogestrel 68-mg implant	Organon (Jersey City, NJ)	0.1	0.1
Copper 380-mm ² IUD	Paragard (Cooper Surgical, Trumbull, CT)	0.6	0.8
Levonorgestrel IUD			
13.5-mg	Skyla (Bayer, Whippany, NJ)	0.3	0.4
19.5-mg	Kyleena (Bayer, Whippany, NJ)	0.2	0.2
52-mg	Liletta (Medicines360, San Francisco, CA; and AbbVie, North Chicago, IL)	0.1	0.1
	Mirena (Bayer, Whippany, NJ)		

IUD, intrauterine device.

SPECIFICATIONS AND MECHANISMS OF ACTION

Although all LARC methods are highly effective contraception, they prevent pregnancy in different ways. The etonogestrel implant is a single flexible radiopaque rod measuring 4 cm long and 2 mm in diameter containing 68 mg of 3-ketodesogestrel, otherwise known as etonogestrel, within a core surrounded by a rate-controlling membrane. When placed subdermally, etonogestrel diffuses from the implant into systemic circulation at concentrations that inhibit ovulation by preventing the mid-cycle luteinizing hormone surge.⁸ Ovarian activity is not fully suppressed, as evidenced by near normal levels of follicle stimulating hormone and estradiol with continued use.

Intrauterine devices do not exert their main effect through systemic mechanisms; rather, they work locally. As a foreign body, all IUDs create a sterile inflammatory response in the endometrial cavity that is spermicidal and prevents fertilization.⁹ In the United States, available IUDs add copper or hormones to increase efficacy, and IUD frames are one of two types. The copper 380-mm² IUD is available on a rigid Tatum-T polyethylene frame in which the arms and the stem meet in a true “T”; for placement, the arms bend downward toward the stem to load into the inserter. The hormonal IUDs are all available on a more flexible Nova-T polyethylene frame; for placement, the arms fold upward above the stem into the inserter.

The copper 380-mm² IUD is 32-mm wide by 36-mm long, with 380 mm² of exposed copper surface area. Unlike earlier versions of the copper IUD that contained copper only on a thin wire wrapped around

the stem, this IUD has bands of copper on each arm. These bands dissolve much more slowly than the copper wire, significantly extending the duration of action. The copper ions adversely affect sperm motility and viability.⁹

The levonorgestrel IUDs have a steroid-releasing reservoir covered by a rate-limiting membrane over the stem.¹⁰ The levonorgestrel 13.5-mg and 19.5-mg IUD frames are 28-mm wide by 30-mm long, and the levonorgestrel 52-mg IUD frame is 32-mm wide by 32-mm long.¹¹ Although levonorgestrel IUDs cause foreign-body reactions and progestin-mediated endometrial changes, the latter being the mechanism through which they decrease bleeding frequency, pregnancy is prevented by thickening of cervical mucous as a barrier to sperm penetration.^{12,13}

EFFICACY

Given that LARCs are not user-dependent after placement, perfect-use and typical-use failure rates are similar. The percentage of people experiencing pregnancy in the first year of use is presented in Table 1. Although these first-year rates are often cited in marketing, efficacy over the duration of action is equally important for LARC methods (Table 2).

Although LARCs are very effective at preventing fertilization, in the rare situation in which pregnancy occurs, ectopic pregnancy must be excluded. Compared with non-contraceptive users, the risk of ectopic pregnancy in LARC users is much lower because the likelihood of fertilization is very low; however, if pregnancy occurs, the likelihood of an extrauterine gestation is higher than the 1% rate in the general population.^{14,15} During 11 international clinical trials, no pregnancies occurred in people with the



Table 2. Long-Acting Reversible Contraceptive Extended Duration of Use Summary

Device	FDA-Approved Duration (y)	Evidence-Based Duration (y)	Cumulative Pregnancy Rate Through Evidence-Based Duration
Etonogestrel 68-mg implant (Nexplanon)	3	5 (without obesity) ^{125,126} 4–5 (with obesity) ¹²⁶	0.6 (0.2–1.8) ¹²⁵
Copper 380-mm ² IUD (Paragard)	10	12 ^{127,128} (consider 15 if aged 45 y or older) ¹²⁹	2.2 ^{*,127}
Levonorgestrel IUD			
13.5-mg (Skyla)	3	3 [†]	0.9 (upper limit CI 1.7%) [†]
19.5-mg (Kyleena)	5	5 [‡]	1.45 (0.82–2.53) [‡]
52-mg (Mirena)	8	8 [§]	1.37 (0.71–2.62) ^{§,65}
52-mg (Liletta)	6	8 [§]	1.37 (0.71–2.62) ^{§,65}

FDA, U.S. Food and Drug Administration; IUD, intrauterine device.

Data are % (95% CI) unless otherwise specified.

* No 95% CI provided.

† Skyla prescribing information, Bayer Healthcare, 2021.

‡ Kyleena prescribing information, Bayer Healthcare, 2021.

§ 1.09 (0.56–2.13) if one pregnancy 4 days after IUD removal during year 7 excluded.

|| Liletta is expected to receive FDA approval for 8 years of use in November 2022.

etonogestrel implant in place; thus, no rate of ectopic pregnancy could be determined.¹⁶ In IUD clinical trials for regulatory approval, approximately 6% of pregnancies were ectopic in copper 380-mm² IUD users (Paragard prescribing information, CooperSurgical, 2020) and 50% of pregnancies were ectopic in levonorgestrel IUD users regardless of dose (Skyla prescribing information, Bayer Healthcare, 2021; Kyleena prescribing information Bayer Healthcare, 2022; Mirena prescribing information, Bayer Healthcare, 2022; Liletta prescribing information, Allergan USA Inc. and Medicines360, 2019). In population-based studies, ectopic pregnancy rates were 20% in a systematic review including 240,000 implant users, 15% in a cohort of approximately 17,000 copper IUD users, and 27% in a cohort of approximately 41,000 levonorgestrel 52-mg IUD users.^{17,18} Because population-based rates are likely more reflective of patients in clinical practice, these rates should be used when counseling regarding ectopic pregnancy risk.

With the rise of the obesity epidemic, it is also important to examine contraceptive efficacy in the context of a typical user. According to the Centers for Disease Control and Prevention, almost half of all U.S. adults have obesity and an additional quarter have overweight.¹⁹ In response to increasing rates of overweight and obesity in contraceptive users in the United States, the U.S. Food and Drug Administration (FDA) recommended in 2007 that hormonal contraceptive studies include participants with overweight and obesity to remain representative of the population who will use the product.²⁰ The efficacy of some contraceptive methods, such as the patch and emergency

contraception pills, are known to be affected by weight.^{21,22} Contraceptive implants rely on ovarian suppression as their primary mechanism of action but have other progestin-mediated effects that may contribute to pregnancy prevention at lower serum etonogestrel levels. No studies have primarily assessed implant efficacy in users with overweight and obesity; secondary analyses from a population-based study of 1,168 implant users, of whom 28% had overweight and 30% had obesity, provide evidence that there is no clinically significant correlation between contraceptive failure and body mass index (BMI, calculated as weight in kilograms divided by height in meters squared).²³ Conversely, given that IUDs have a local mechanism of action, it follows that their efficacy should not change in relation to body weight; this is also supported by findings from 4,200 users of the copper or levonorgestrel IUD, of whom 27% had overweight and 35% had obesity, in the aforementioned cohort study.²³

INITIATION CONTRAINDICATIONS AND CONSIDERATIONS

If pregnancy has been reasonably excluded, LARCs can be initiated in most people. Uterine cavity anomalies, untreated cervical cancer, and active pelvic infection are contraindications to IUD placement.²⁴ Uterine cavity anomalies, including congenital anomalies (eg, septate and bicornuate uterus) and other structural anomalies (eg, cavity-distorting leiomyoma, uterine synechiae), may increase the risk of complications such as expulsion and decrease contraceptive efficacy. A review of the literature assessing the safety



and efficacy of IUD use in patients with müllerian anomalies or uterine synechiae found 19 case reports or case series with reported complications of expulsion, pregnancy, bleeding, perforation, and pain; some cases did not report complications.²⁵ Regarding leiomyoma, a systematic review evaluated eight studies that reported on hormonal IUD expulsion rates among women with uterine leiomyomas and concluded that expulsion rates may be higher in this group, although no comparative studies achieved a statistically significant difference in expulsion rates between women with leiomyomas and those without leiomyomas.²⁶ Given the limited data, IUDs cannot be recommended for patients with uterine cavity distortion seeking contraception. Intrauterine devices may be considered for those seeking only noncontraceptive IUD benefits who are willing to accept the possible increased risk of expulsion or other complications.

Implant and hormonal IUD use is restricted in some medical conditions, such as breast cancer, severe decompensated liver disease, hepatocellular adenoma, and malignant liver tumors.²⁴ Certain enzyme-inducing anticonvulsants may decrease the efficacy of an etonogestrel implant, and drug interactions were found to account for 4% of method failures in a study of 234 reported pregnancies during implant use.²⁷ Age and parity should not affect eligibility for LARC use. Implants and IUDs are appropriate and recommended if desired by adolescents and young people without a history of prior pelvic examination or pregnancy.^{28,29}

After placement, follow-up with a health care professional for a routine IUD string check in an asymptomatic patient is not recommended by the U.S. Selected Practice Recommendations for Contraceptive Use³⁰; furthermore, counseling patients to self-check their IUD strings has been shown to have limited clinical utility and may lead to increased patient anxiety and unnecessary visits.³¹ Instead, counseling patients on unexpected symptoms and signs of expulsion may permit patients to self-identify a problem and present for follow-up.

PLACEMENT TIMING

Although interval placement (anytime 4 weeks or more postpregnancy) is the most common time for LARC initiation, postpregnancy placement has been increasingly studied and performed. Implant placement at the time of medication abortion or immediately after early pregnancy uterine aspiration is safe.^{32–35} Placing an implant at the time of initiating medication abortion with mifepristone does not

change treatment outcome and should be considered based on patient preference and plan for follow-up.³⁴ Two population studies report decreased repeat pregnancy and abortion in the 2 years after immediate postabortion implant placement.^{33,35} Intrauterine devices can be placed immediately after uterine evacuation in the first or second trimester or at time of completed medication abortion; immediate placement reduces rapid repeat pregnancy without increasing infection or expulsion risk compared with delayed placement.^{35–39}

Both postpartum implant placement before hospital discharge and immediate postplacental IUD placement are safe, convenient, and result in high method-continuation rates and low repeat-pregnancy rates within the first year.^{40,41} Despite theoretical concerns about the effects of exogenous progestins on breastfeeding, data suggest that the etonogestrel implant and levonorgestrel IUD and have no effect on breastfeeding initiation, continuation, or infant growth.^{42–46} An important caveat is that perforation risk is higher in people who are breastfeeding; a systematic review concludes that the risk of perforation during IUD placement in people who are breastfeeding is 6–10 times greater than in those who are not breastfeeding.⁴⁷ There are limited data regarding perforation risk with immediate postplacental IUD placement.

Expulsion is one significant disadvantage of immediate postplacental IUD placement. According to a systematic review and meta-analysis, among IUDs placed immediately after vaginal birth, the expulsion rate was 27% for the levonorgestrel 52-mg IUD and 12% for the copper IUD; on average, this represents an eightfold increase over expulsion rates after interval placement.⁴⁸ Expulsion rates were greater in placement after vaginal birth compared with cesarean birth (adjusted risk ratio 4.57) and greater with levonorgestrel compared with copper IUDs (adjusted risk ratio 1.9). This meta-analysis included studies with various durations of follow-up from 1 month to 5 years, though expulsion rates did not differ for studies with follow-up at 3–6 months compared with greater than 6 months, implying that most expulsions occurred early. In addition, a recent population-based study shows that, compared with IUDs placed more than 1 year from birth, the adjusted hazard ratio for expulsion was highest for placements 0–3 days postpartum (5.34), lower at 4 days–6 weeks postpartum (1.22), and lowest at 6–14 weeks postpartum (1.06).⁴⁹ Other concerns after immediate postpartum IUD placement include malposition and missing strings;



in one cohort of 348 people who underwent immediate postpartum IUD placement and were monitored for 12 months, 21% of IUDs in situ lacked visible strings.⁵⁰

The ability to follow up may be a key factor when weighing the risks and benefits of immediate postpartum IUD placement. Among participants who completed follow-up, two U.S. randomized controlled trials comparing immediate postpartum IUD placement with delayed placement found no difference in use at 6 months⁵¹ and 12 months⁵² after allowing for postexpulsion replacement. In both clinical trials and population-based studies, postpartum follow-up rates are higher in patients with private insurance and lower in those with Medicaid insurance.^{53,54} In addition, for patients with Medicaid insurance, funding may be more reliable in the immediate and early postpartum period due to lack of Medicaid expansion in some states.⁵⁵ These findings suggest that those least likely to be able to attend follow-up appointments have the most potential benefit from immediate placement.

In summary, immediate postpartum IUD placement should be personalized as opposed to universal. If patients are likely to retain health care funding and attend their postpartum follow-up appointments, the risks of immediate postpartum IUD placement may outweigh the advantages. Informing patients of the available data may empower them to choose the ideal type and timing of postpartum LARCs, if desired. Patients who choose immediate postpartum IUD placement should be thoroughly counseled on recognizing expulsion and given a plan for back-up contraception and follow-up if an expulsion is recognized. Furthermore, if an immediate postpartum LARC method is strongly desired but the expulsion risk is unacceptable to the patient, emphasis should be placed on the implant.

PLACEMENT COMPLICATIONS

Although placement and removal of LARC methods has become routine for most clinicians, growing experience has brought new clinical challenges for both implants and IUDs.

Implant

Implant placement can routinely cause a small scar and mild pain, swelling, and bruising. A pressure dressing applied for 24 hours may decrease bruising and swelling. Patients should be instructed to apply ice and use anti-inflammatory medications for postplacement discomfort. Infection at the placement site is extremely rare but could require oral antibiotics and consideration for removal depending on infection

extent and response to treatment (Nexplanon prescribing information, Organon, 2021). Improper placement is arguably the most serious complication, because it can have lasting repercussions for the patient. The original implant inserter, introduced in 2006, was a two-handed inserter with the benefit of providing the clinician with an unobstructed view of the inserter needle. Subsequently, in 2010, the one-handed inserter was introduced, and barium sulfate was added to the implant to make it radiopaque.⁵⁶ This inserter features a depth guide designed to minimize risk of improper placement, although with the consequence of blocking the clinician's view of the inserter needle from above, requiring clinicians to attempt to view the inserter needle from the side.

Though most implants are easily removed, 14 per 1,000 removals are reported by health care professionals as difficult and 1 per 1,000 implants are nonpalpable.^{57,58} The importance of postplacement implant palpation by the clinician and patient is highlighted by the fact that "missing implants" attributed to nonplacement accounted for 26% of 463 pregnancies in implant users in a population study.²⁷ The etonogestrel 68-mg implant is meant to be placed in the subcutaneous tissues of the upper arm over the triceps, 8–10 cm proximal to the medial epicondyle. Less than 8 cm from the medial epicondyle, the ulnar nerve is more superficial and could be injured by implant placement. The triceps region is a change from prior recommendations to place the implant over the sulcus, or the groove between the biceps and triceps muscles, and was made to improve safety because there are no neurovascular structures in this area.⁵⁹ If the implant cannot be easily palpated immediately after placement, it should be removed at that time and replaced through a different incision.

Intrauterine Device

Anticipated or perceived pain during IUD placement can be a barrier for some patients,⁶⁰ and an array of methods to improve pain with placement have been studied. A 2015 review concluded that there was no evidence of reduced pain with lidocaine 2% gel, misoprostol, and most nonsteroidal anti-inflammatory drugs (NSAIDs). Of the NSAIDs, oral naproxen was shown to reduce pain scores in one of two trials and intramuscular ketorolac reduced pain in a study for nulliparous patients only.⁶¹

Recent studies consistently show that a paracervical lidocaine block reduces pain in certain populations.^{62–64} Randomized controlled studies in people who are nulliparous or nulligravid show that a 10–20-mL 1% lidocaine paracervical block decreased



pain during IUD placement. These studies included copper IUDs and all doses and sizes of hormonal IUDs; thus, they provide evidence of improved placement pain with paracervical block with all IUD types. Although a paracervical block may cause pain with injection and slight prolongation of the procedure, patients who are nulliparous or who may require cervical dilation should be offered this option.

Placement of IUDs with smaller frames and inserters may be presumed to be easier or less painful, but the available data do not favor a significant clinical difference. As stated previously, the levonorgestrel 13.5-mg and 19.5-mg IUD frames are 28-mm wide by 30-mm long, and the levonorgestrel 52-mg frame is 32-mm wide by 32-mm long. The outer diameter of the placement tube is 3.8 mm for the levonorgestrel 13.5-mg and 19.5-mg IUDs; it is 4.4 mm for the Mirena and 4.8 mm for the Liletta (Skyla prescribing information, Bayer Healthcare, 2021; Kyleena prescribing information Bayer Healthcare, 2022; Mirena prescribing information, Bayer Healthcare, 2022; Liletta prescribing information, Allergan USA Inc. and Medicines360, 2019). A randomized trial comparing the levonorgestrel 13.5-mg, 19.5-mg, and 52-mg IUDs found that, although more investigators evaluated placement as “easy” and more patients reported no pain with the levonorgestrel 13.5-mg and 19.5-mg IUDs, there were similarly low rates among the groups of “very difficult” placement or placement with “severe” pain.¹¹ Given that the levonorgestrel 52-mg IUDs have longer duration of use and significantly higher rates of absent or infrequent bleeding,⁶⁵ the levonorgestrel IUD 13.5-mg and 19.5-mg IUDs should be considered in appropriately counseled patients who do not prefer absence of bleeding or spotting or have other unique considerations (Table 3).

Perforation at time of IUD placement is rare; rates are 2 in 1,000 or less in clinical trials (Paragard prescribing information, CooperSurgical, 2020; Skyla prescribing information, Bayer Healthcare, 2021; Kyleena prescribing information Bayer Healthcare,

2021; Mirena prescribing information, Bayer Healthcare, 2022; Liletta prescribing information, Allergan USA Inc. and Medicines360, 2019) and approximately 2 per 1,000 in population-based studies.⁶⁶ Because patients may have minimal to no symptoms at time of perforation, a high index of suspicion must be maintained because the risks of laparoscopy to remove an intra-abdominal IUD far outweigh the risks of unnecessary removal and replacement. Signs of perforation may include a loss of resistance or greater than anticipated depth during sounding or IUD placement, unusual pain, or brisk bleeding. If perforation is suspected at time of placement, the IUD position should be confirmed by ultrasonography. If appropriate positioning cannot be confirmed, the IUD should be immediately removed. Uterine healing after perforation can be rapid, as evidenced by cases of laparoscopy shortly after identified perforations⁶⁷; repeat placement should be delayed 2–6 weeks, and asymptomatic stable patients can often be discharged home with return precautions.

Although active pelvic infection is a contraindication to IUD placement, new pelvic infection is diagnosed in only 0.5% of people within 90 days.⁶⁸ Screening for sexually transmitted infections at time of IUD placement is recommended only if clinically indicated, and prophylactic antibiotics are not recommended. Traditional teaching was that infection risk is highest in the first 20 days after IUD placement, but recent evidence from a levonorgestrel 52-mg IUD clinical trial monitoring participants for 2 years after placement suggests that infections are infrequent and not temporally related to placement.⁶⁹ A 5-year randomized trial with people at low-risk for pelvic infection shows a significantly lower rate in participants aged 25 years or younger among levonorgestrel 52-mg IUD users compared with a comparator copper IUD; this suggests that progestin-mediated cervical thickening may play a role in infection prevention.⁷⁰ If pelvic infection develops in a patient with an IUD, treatment per Centers for Disease Control and Prevention guidelines should be provided. Only if the

Table 3. Comparison of Characteristics of Levonorgestrel Intrauterine Devices

Levonorgestrel IUD type	Frame Size (mm)	Inserter Diameter (mm)	Absence of Bleeding or Spotting Rate at 1 y ^{114,115}	Absence of Bleeding or Spotting Rate at 3 y ^{114,115}
13.5-mg (Skyla)	28×30	3.8	6	12
19.5-mg (Kyleena)	28×30	3.8	12	20
52-mg (Liletta)	32×32	4.8	19–20	36–37
52-mg (Mirena)	32×32	4.4	19–20	36–37

IUD, intrauterine device.

Data are % unless otherwise specified.



patient fails to improve after 48–72 hours should IUD removal be considered.³⁰

REMOVAL CHALLENGES

Implant

After incision of the skin, implant removal can be accomplished with or without instruments and is best performed with techniques with which the operator feels most comfortable. Removal of palpable implants with a “pop-out” technique is well-described for multiple rod implants and is therefore a quick and efficient methodology with a single rod implant.⁷¹ Regardless of technique, removal efficiency can be maximized by remembering a few key points. First, the local anesthetic should be injected under the implant tip, preferably while holding the proximal tip of the implant with the nondominant forefinger and elevating and stabilizing the distal tip with the dominant thumb. Using small amounts of anesthetic placed strategically will minimize fluid obliteration around the distal tip, which can make the implant difficult to palpate after injection. Second, the incision should always be made longitudinally in line with the long axis of the implant to prevent implant fracturing. Lastly, nonpalpable implant removal should be performed only by clinicians experienced with this complication.⁷²

Three case series describe referral center experience with nonpalpable implant removal.^{73–75} In these case series, approximately 90% of people referred were confirmed to have a nonpalpable implant. Almost all implants were able to be localized by high-frequency ultrasonography, with few requiring other imaging modalities. Although most implants were in the subcutaneous fat, approximately one third were found to be inserted below the fascia. Office removal by a specialist was successful at least 97% of the time if the implant was above the fascia, with slightly lower rates of success for subfascial implants (83–92% in the two case series in which this rate was reported). In cases of unsuccessful office removal or if the implant is close to neurovascular structures, patients are referred to a surgeon specializing in arm and axillary dissection.

Lessons about proper placement can be learned from cases of difficult removal. Subfascial implants were more common in patients with underweight or normal weight (BMI lower than 25).⁷⁴ This is likely due to the thin layer of subcutaneous tissue between the dermis and the fascia in such individuals, and it makes awareness of appropriate subdermal placement per manufacturer’s instructions even more crucial in this population. There are also data to suggest a poten-

tial association between replacement through a removal incision and subfascial placement. Although this has not been studied directly, the mechanism of decreased resistance through a prior incision makes causation plausible; thus, caution should be used, and replacement through a separate incision should be considered, especially in thin patients.

Intrauterine Device

There are few indications for IUD removal based on its position in the uterine cavity. Studies evaluating IUD location by ultrasonography have demonstrated spontaneous positional adjustments as well as changes in the appearance of positioning with normal growth and thinning of the endometrium.^{76,77} Removal for partial expulsion should be reserved for patients with significant correlating symptoms such as increased bleeding or cramping, ultrasonographic evidence of the IUD stem in the cervical canal, or visualization of the stem protruding through the external cervical os. Embedment refers to penetration of an IUD into the myometrium without extension through the serosa. Recent advances in ultrasonographic technology and three-dimensional imaging have led to increased referrals for asymptomatic patients with possible IUD embedment. Although continued surveillance for the development of corresponding symptoms may be warranted in these circumstances, removal is not necessarily indicated.

Intrauterine devices available in the United States have strings that are meant to come through the external cervical os and sit in the upper vagina after placement. Intrauterine device strings are present to increase ease of removal, but lack of strings is not an indication for intervention. The copper 380-mm² IUD has white strings, the levonorgestrel 13.5-mg IUD has brown strings, the levonorgestrel 19.5-mg IUD has blue strings, and the levonorgestrel 52-mg IUDs have blue (Liletta) or brown (Mirena) strings (Paragard prescribing information, CooperSurgical, 2020; Skyla prescribing information, Bayer Healthcare, 2021; Kyleena prescribing information Bayer Healthcare, 2021; Mirena prescribing information, Bayer Healthcare, 2022; Liletta prescribing information, Allergan USA Inc. and Medicines360, 2019). Some IUDs available outside the United States do not have strings. A properly positioned IUD with missing or no strings can remain in situ until removal is desired or device expiration is reached. At time of removal, after confirmation of IUD location with ultrasonography, an in-office attempt is preferable if the patient is amenable. A paracervical block can be offered, and concurrent abdominal ultrasound guidance is helpful. An



IUD thread retriever can be used and may work up to 50% of the time.⁷⁸ Although there are case reports of successful T-shaped IUD removal with an IUD hook, this instrument is designed and intended for removal of ring IUDs.⁷⁹ Long, narrow instruments with jaws that open only at the distal end, such as alligator forceps or hysterographic grasping forceps, can be used with higher rates of successful removal (83–98%); if not successful, a manual vacuum aspiration device can be used to attempt removal through suction.^{80–84} Intrauterine devices that appear to be embedded can still be removed in this manner,⁸⁵ although IUD fracturing, or breaking, can be noted.⁸⁶ In our experience, the Tatum-T IUD frames such as in the copper 380-mm² IUD are more prone to this complication. Given that IUDs are inert substances after depletion of their hormonal or copper components, careful consideration of fertility goals and counseling of risks and benefits should guide plans for operative removal, especially in those requiring destructive procedures to remove embedded IUD fragments.

When pregnancy occurs with an IUD in place, the risk of extrauterine location is significantly increased.¹⁸ Therefore, the first and most important step is to rule out ectopic pregnancy. If ectopic pregnancy is confirmed, IUD removal is recommended; pregnancy with an IUD in place is rare, and one must wonder what made this particular IUD fail (eg, a manufacturing defect). A new IUD should be placed if the patient desires to continue this method. In all other pregnancies with an IUD in situ, a removal attempt should be considered as soon as possible regardless of pregnancy intentions. However, if the pregnancy is undesired, there are fewer concerns when attempting immediate removal. If the patient wishes to continue the pregnancy, the IUD should always be removed after appropriate counseling if strings are visible or if ultrasonography confirms its presence within the cervix. Pregnant patients with retained IUDs in pregnancy are at greater risk of spontaneous abortion, septic abortion, preterm delivery, and chorioamnionitis.⁸⁷ In a comparative cohort study of 144 pregnancies in patients with IUDs in situ, the combined risk of adverse pregnancy outcomes was significantly higher in patients who retained their IUD compared with those who had them removed during the first trimester (relative risk 2.0, 95% CI 1.3–3.3), especially in patients who retained an IUD in a low-lying position (relative risk 3.9, 95% CI 1.8–8.6); removal was performed only in patients with visible IUD strings.⁸⁸ If no strings are present and ultrasonography confirms an intrauterine IUD below the level of the pregnancy, ultrasound-guided removal

with forceps or hysteroscopy can be attempted after thorough counseling of the risks and benefits of attempted IUD removal compared with the increased obstetric risks of IUD retention.⁸⁹ Removal should not be attempted if the IUD is superior to the gestational sac. If the IUD is not located on ultrasonogram, an X-ray of the abdomen and pelvis should be performed after the first trimester or pregnancy resolution to confirm expulsion.

Levonorgestrel IUD use in perimenopause and menopause is safe and has benefits in several clinical scenarios. During perimenopause, contraception remains necessary because occasional ovulation occurs.^{90,91} In addition, people who are perimenopausal and experience heavy or frequent bleeding may undergo uncomfortable and time-consuming evaluation to rule out endometrial cancer; this may be avoided in those with lighter or absent bleeding with a levonorgestrel IUD in place through the menopausal transition. In patients with menopausal symptoms desiring hormone therapy, a levonorgestrel 52-mg IUD can be used for endometrial protection in place of a systemic progestin.^{92–94} Because the copper IUD does not have hormonal benefits, removal is reasonable after confirmation of menopausal status. Although no studies have examined the risks of retaining an IUD long-term in asymptomatic people who are menopausal, retention of an inert IUD can be considered if removal risks outweigh benefits.⁹⁵

INTRAUTERINE DEVICES AS EMERGENCY CONTRACEPTION

Emergency contraception, or contraception used after unprotected or inadequately protected intercourse to reduce the risk of pregnancy, continues to evolve. Methods such as ulipristal acetate and levonorgestrel pills are no more effective than placebo in individuals with BMIs of 35 or higher and 26 or higher, respectively.²² In contrast, the copper IUD remains an effective method of emergency contraception unaffected by weight, with a window of at least 5 days after intercourse.⁹⁶ Consideration for placement after 5 days may be supported by an analysis of data from four studies in which no pregnancies occurred in patients with negative urine pregnancy test results who had copper 380-mm² IUDs placed after unprotected intercourse in the prior 6–14 days.⁹⁷ Placement of an IUD as emergency contraception has the benefit of providing long-term contraception, but use can be limited by barriers to access. Furthermore, people considering an IUD more commonly choose a levonorgestrel than a copper IUD, likely due to the hormonal effect on menstrual bleeding and dysmenorrhea.⁹⁸ A recent



randomized trial shows that the levonorgestrel 52-mg IUD was noninferior to the copper IUD for emergency contraception (0.3% vs 0% pregnancy rate).⁹⁹ Further study is needed to definitively understand differences in outcomes between the levonorgestrel IUD and the copper IUD for emergency contraception, although secondary analyses of this study have salient implications on recommendations for same-day levonorgestrel IUD placement as well as need for postplacement back-up contraception.^{100,101}

BLEEDING PATTERNS

Implant

The etonogestrel implant is well known for its typically light yet unpredictable bleeding pattern; thus, it can be difficult to counsel patients on what to expect after placement. Continuous systemic progestin exposure can result in bleeding due to the atrophic endometrium with dilated, thin-walled vessels.¹⁰² Although only 13% of patients discontinued implant use due to bleeding symptoms in U.S. phase 3 clinical trials,¹⁰³ clinical use in a population-based study in St. Louis shows a 44% discontinuation rate at 3 years, with approximately half of users citing bleeding changes as the reason for removal.¹⁰⁴ For a given 90-day reference period, approximately 50% of implant users experienced no or infrequent bleeding, with roughly 25% experiencing frequent or prolonged bleeding.¹⁰⁵ There was no consistent pattern of worsening or improving over time, although those who reported absent, infrequent, or normal frequency of bleeding within the first 3 months of use tended to continue these patterns over the next 2 years and those with frequent or prolonged bleeding initially had a 50% chance that their bleeding would improve in the subsequent 90 days.¹⁰⁶

Because the implant has very high contraceptive efficacy, users may desire treatment for bleeding symptoms rather than removal. Several modalities have been studied and found to modestly or temporarily address bleeding symptoms. Investigated methods include cyclic and continuous combined oral contraceptive (COC) pills, progestin-only pills, NSAIDs, tranexamic acid, ulipristal acetate, and tamoxifen.^{107,108} Combined oral contraceptive pills are easily accessible and well-studied compared with other options. Two randomized controlled trials investigated the effect of concurrent implant and continuous COC pill use.^{109,110} Results show that a 14- to 28-day course of COCs improved bleeding in most users, although bothersome bleeding resumed after pill discontinuation. Furthermore, of users who desired removal initially, most requested removal

after study completion despite bleeding improvement while on COCs.¹⁰⁹ For patients with no contraindication to estrogen use who prefer to attempt intervention before removal, initial management with continuous COCs for 4 weeks is reasonable, with the option to continue use if a desirable bleeding pattern is obtained. One small study evaluated combined implant and COC use for up to 6 months without any significant adverse effects.¹¹¹

Intrauterine Device

The copper IUD is associated with increased dysmenorrhea and volume and length of menstrual bleeding, especially within the first several cycles after placement. These effects generally decrease over time¹¹² but are a reason for discontinuation in 2.4% of users in the first year.¹¹³ Conversely, levonorgestrel IUDs decrease bleeding and improve dysmenorrhea through down-regulation of endometrial estrogen receptors and decreased endometrial proliferation.¹²

In levonorgestrel 52-mg IUD clinical trials, rates of absent bleeding, spotting, and light bleeding increased annually up to 3–5 years of use, at which time they accounted for 89% of bleeding patterns. *Absent bleeding or spotting* rates, defined as no bleeding within the previous 90 days, were 19% at 1 year, 37% at 3 years, and approximately 37–42% through 8 years of continuous use.^{65,114} Comparatively, levonorgestrel 13.5-mg and 19.5-mg IUD users had lower absent bleeding or spotting rates and infrequent bleeding rates.¹¹⁵ At 1 year, absent bleeding or spotting rates were 6% and 12%, respectively, for the levonorgestrel 13.5-mg IUD and 19.5-mg IUD, increasing to 12% and 20%, respectively, at 3 years. Users of these IUDs also had higher rates of irregular bleeding at 3 years compared with levonorgestrel 52-mg IUD users (23% of levonorgestrel 13.5-mg IUD users, 17% of levonorgestrel 19.5-mg IUD users, and 6% of levonorgestrel 52-mg IUD users).

Given the favorable and consistent bleeding profile of the levonorgestrel 52-mg IUD as well as its ability to inactivate the endometrium, it has been used for multiple noncontraceptive benefits. These include management of heavy menstrual bleeding,¹¹⁶ primary dysmenorrhea,¹¹⁷ endometriosis,¹¹⁸ leiomyoma,¹¹⁹ adenomyosis,¹²⁰ menstrual bleeding in people with hemostatic disorders¹²¹ or on anticoagulation,¹²² and in patients with endometrial intraepithelial neoplasia and low-risk endometrial cancer.¹²³

EVIDENCE-BASED DURATION OF USE

Ongoing research has shown that LARC methods are effective for contraception beyond their initial



approved duration of use (Table 2). The FDA supports off-label use in informed patients when adequate published evidence is available.¹²⁴ For people who desire long-term pregnancy prevention, extending duration of use minimizes removal and replacement procedures and decreases associated health care costs. All patients should be counseled regarding best evidence for LARC use. If clinicians are uncomfortable recommending extended duration based on the evidence, the patient can be referred for consultation with a complex family planning specialist. Clinicians should be aware that users may desire removal and replacement before evidence-based expiration; this practice should be individualized, with counseling of the risks and benefits of removal and replacement.

Implant

The etonogestrel 68-mg implant is FDA-approved for 3 years (Nexplanon prescribing information, Organon, 2021). Data support use up to 5 years in individuals without obesity. A World Health Organization study showed no pregnancies in years 4 and 5 of use, but only 6% of implants users who started the study had obesity.¹²⁵ The best data for extended use in users with obesity are provided by the Contraceptive CHOICE study. Approximately 100 users with obesity continued the implant for 4 years, and few continued to 5 years; no pregnancies occurred.¹²⁶ Although some institutions have chosen to recommend extended use of the etonogestrel 68-mg implant up to 5 years regardless of BMI, users with obesity should be counseled regarding available evidence when choosing to extend use past 4 years.

Intrauterine Device

Current FDA-approved use of the copper 380-mm² IUD is 10 years (Paragard prescribing information, CooperSurgical, 2020), but evidence supports at least 12 years of use. Data from the initial clinical trial included 78 people with use to 12 years, during which time no pregnancies occurred,¹²⁷ and the safety and efficacy of 12 years of use is supported by subsequent studies based on 1,204 woman-years of observations.¹²⁸ There are fewer data regarding use for between 12 and 15 years, with less than 100 woman-years of observations, and most users were aged 40 years or older at the time of 10 years of completed use.¹²⁹ In the context of decreased natural fertility, we recommend shared decision making for extending use to between 12 and 15 years in users aged 45 years and older.

The two U.S.-marketed levonorgestrel 52-mg IUDs are equivalent based on initial dose and release

rates of their levonorgestrel component.¹³⁰ As such, data regarding duration of use can be applied equally to both products. Liletta is currently FDA-approved for 6 years of use (Liletta prescribing information, Allergan USA Inc. and Medicines360, 2019), and Mirena was approved for 8 years of use in 2022 (Mirena prescribing information, Bayer Healthcare, 2022). Liletta is expected to receive FDA approval for 8 years of use in November 2022. Recent data support the continued use of the levonorgestrel 52-mg IUD for at least 8 years, with low incidence of adverse events.⁶⁵ There is no evidence for extended use for the levonorgestrel 13.5-mg or 19.5-mg IUDs.

CONCLUSION

Although LARC methods are increasingly used for contraception, their use is not without clinical challenges. Notable updates include evidence-based duration of use, LARCs as emergency contraception, and guidance for implant placement and nonpalpable implant removals. An understanding of ongoing LARC developments is critical to providing patients with the most up-to-date and evidence-based counseling and care. Complex family planning has continued to grow as it takes a step forward as a subspecialty newly recognized by the American Board of Obstetrics and Gynecology.¹³¹ Although all obstetrician-gynecologists as well as primary care clinicians can safely provide LARCs, complex family planning specialists are an expert referral source for challenging cases and evidence-based care as contraceptive technology continues to develop.

REFERENCES

1. Jensen JT, Creinin MD. Contraception, population, and the environment. In: Jensen JT, Creinin MD, editors. *Speroff and Darney's Clinical Guide to Contraception*. 6th ed. Wolters Kluwer; 2019.
2. Kavanaugh ML, Pliskin E. Use of contraception among reproductive-aged women in the United States, 2014 and 2016. *F S Rep* 2020;1:83–93. doi: 10.1016/j.xfre.2020.06.006
3. Finer LB, Zolna MR. Declines in unintended pregnancy in the United States, 2008–2011. *N Engl J Med* 2016;374:843–52. doi: 10.1056/NEJMsa1506575
4. McNicholas C, Madden T, Secura G, Peipert JF. The contraceptive CHOICE project round up: what we did and what we learned. *Clin Obstet Gynecol* 2014;57:635–43. doi: 10.1097/GRF.000000000000070
5. Ricketts S, Klingler G, Schwalberg R. Game change in Colorado: widespread use of long-acting reversible contraceptives and rapid decline in births among young, low-income women. *Perspect Sex Reprod Health* 2014;46:125–32. doi: 10.1363/46e1714
6. Creinin M, Kohn JE, Tang JH, Serna TB. Society of family planning clinical affairs committee. Society of family planning committee statement on IUD nomenclature. *Contraception* 2022;106:1–2. doi: 10.1016/j.contraception.2021.10.017



7. Higgins JA. Celebration meets caution: LARC's boons, potential busts, and the benefits of a reproductive justice approach. *Contraception* 2014;89:237–41. doi: 10.1016/j.contraception.2014.01.027
8. Bennink HJ. The pharmacokinetics and pharmacodynamics of Implanon, a single-rod etonogestrel contraceptive implant. *Eur J Contracept Reprod Health Care* 2000;5(Suppl 2):12–20. doi: 10.1080/13625187.2000.12067162
9. Johannisson E. Mechanism of action of intrauterine devices: biochemical changes. *Contraception* 1987;36:11–22. doi: 10.1016/0010-7824(87)90058-8
10. Hsia JK, Creinin MD. Intrauterine contraception. *Semin Reprod Med* 2016;34:175–82. doi: 10.1055/s-0036-1571438
11. Gemzell-Danielsson K, Schellschmidt I, Apter D. A randomized, phase II study describing the efficacy, bleeding profile, and safety of two low-dose levonorgestrel-releasing intrauterine contraceptive systems and Mirena. *Fertil Steril* 2012;97:616–22.e1–3. doi: 10.1016/j.fertnstert.2011.12.003
12. Critchley HO, Wang H, Jones RL, Kelly RW, Drudy TA, Gebbie AE, et al. Morphological and functional features of endometrial decidualization following long-term intrauterine levonorgestrel delivery. *Hum Reprod* 1998;13:1218–24. doi: 10.1093/humrep/13.5.1218
13. Lewis RA, Taylor D, Natavio MF, Melamed A, Felix J, Mishell D Jr. Effects of the levonorgestrel-releasing intrauterine system on cervical mucus quality and sperm penetrability. *Contraception* 2010;82:491–6. doi: 10.1016/j.contraception.2010.06.006
14. A multinational case-control study of ectopic pregnancy. The World Health Organization's special programme of research, development and research training in human reproduction: task force on intrauterine devices for fertility regulation. *Clin Reprod Fertil* 1985;3:131–43.
15. Hoover KW, Tao G, Kent CK. Trends in the diagnosis and treatment of ectopic pregnancy in the United States. *Obstet Gynecol* 2010;115:495–502. doi: 10.1097/AOG.0b013e3181d0c328
16. Darney P, Patel A, Rosen K, Shapiro LS, Kaunitz AM. Safety and efficacy of a single-rod etonogestrel implant (Implanon): results from 11 international clinical trials. *Fertil Steril* 2009;91:1646–53. doi: 10.1016/j.fertnstert.2008.02.140
17. Callahan R, Yacobson I, Halpern V, Nanda K. Ectopic pregnancy with use of progestin-only injectables and contraceptive implants: a systematic review. *Contraception* 2015;92:514–22. doi: 10.1016/j.contraception.2015.08.016
18. Heinemann K, Reed S, Moehner S, Minh TD. Comparative contraceptive effectiveness of levonorgestrel-releasing and copper intrauterine devices: the European Active Surveillance Study for Intrauterine Devices. *Contraception* 2015;91:280–3. doi: 10.1016/j.contraception.2015.01.011
19. Fryar CD, Carroll MD, Afful J. Prevalence of overweight, obesity, and severe obesity among adults aged 20 and over: United States, 1960–1962 through 2017–2018. *NCHS Health E-Stats*; 2020.
20. Trussell J, Portman D. The creeping Pearl: why has the rate of contraceptive failure increased in clinical trials of combined hormonal contraceptive pills? *Contraception* 2013;88:604–10. doi: 10.1016/j.contraception.2013.04.001
21. Ziemann M, Guillebaud J, Weisberg E, Shangold GA, Fisher AC, Creasy GW. Contraceptive efficacy and cycle control with the Ortho Evra/Evra transdermal system: the analysis of pooled data. *Fertil Steril* 2002;77(2 Suppl 2):S13–8. doi: 10.1016/s0015-0282(01)03275-7
22. Glasier A, Cameron ST, Blithe D, Scherrer B, Mathe H, Levy D, et al. Can we identify women at risk of pregnancy despite using emergency contraception? Data from randomized trials of ulipristal acetate and levonorgestrel. *Contraception* 2011;84:363–7. doi: 10.1016/j.contraception.2011.02.009
23. Xu H, Wade JA, Peipert JF, Zhao Q, Madden T, Secura GM. Contraceptive failure rates of etonogestrel subdermal implants in overweight and obese women. *Obstet Gynecol* 2012;120:21–6. doi: 10.1097/AOG.0b013e318259565a
24. Curtis KM, Tepper NK, Jatlaoui TC, Berry-Bibee E, Horton LG, Zapata LB, et al. U.S. Medical eligibility criteria for contraceptive use. *MMWR Recomm Rep* 2016;65:1–103. doi: 10.15585/mmwr.rr6503a1
25. Tepper NK, Zapata LB, Jamieson DJ, Curtis KM. Use of intrauterine devices in women with uterine anatomic abnormalities. *Int J Gynaecol Obstet* 2010;109:52–4. doi: 10.1016/j.ijgo.2009.10.022
26. Xie ZW, Zhang YN, Wan S, Xu WZ, Chen J. Levonorgestrel-releasing intrauterine device is an efficacious contraceptive for women with leiomyoma. *J Int Med Res* 2012;40:1966–72. doi: 10.1177/030006051204000538
27. Rowlands S, Cornforth E, Harrison-Woolrych M. Pregnancies associated with etonogestrel implants in the UK: comparison of two 5-year reporting periods. *BMJ Sex Reprod Health* 2019 Oct 10 [epub ahead of print]. doi: 10.1136/bmjshr-2019-200338
28. Mestad R, Secura G, Allsworth JE, Madden T, Zhao Q, Peipert JF. Acceptance of long-acting reversible contraceptive methods by adolescent participants in the Contraceptive CHOICE Project. *Contraception* 2011;84:493–8. doi: 10.1016/j.contraception.2011.03.001
29. Jatlaoui TC, Riley HEM, Curtis KM. The safety of intrauterine devices among young women: a systematic review. *Contraception* 2017;95:17–39. doi: 10.1016/j.contraception.2016.10.006
30. Curtis KM, Jatlaoui TC, Tepper NK, Zapata LB, Horton LG, Jamieson DJ, et al. U.S. selected practice recommendations for contraceptive use, 2016. *MMWR Recomm Rep* 2016;65:1–66. doi: 10.15585/mmwr.rr6504a1
31. Melo J, Tschann M, Soon R, Kuwahara M, Kaneshiro B. Women's willingness and ability to feel the strings of their intrauterine device. *Int J Gynaecol Obstet* 2017;137:309–13. doi: 10.1002/ijgo.12130
32. Zheng W, Tang Y, Wang C, Niu X, Qian Z, Huang L. Three-year observational study of immediate post-abortion insertion versus menstrual insertion of etonogestrel contraceptive implant. *BMC Womens Health* 2021;21:436. doi: 10.1186/s12905-021-01542-8
33. Rose SB, Garrett SM, Stanley J. Immediate postabortion initiation of levonorgestrel implants reduces the incidence of births and abortions at 2 years and beyond. *Contraception* 2015;92:17–25. doi: 10.1016/j.contraception.2015.03.012
34. Raymond EG, Weaver MA, Tan YL, Louie KS, Bousiéguéz M, Lugo-Hernández EM, et al. Effect of immediate compared with delayed insertion of etonogestrel implants on medical abortion efficacy and repeat pregnancy: a randomized controlled trial. *Obstet Gynecol* 2016;127:306–12. doi: 10.1097/AOG.0000000000001274
35. Cameron ST, Glasier A, Chen ZE, Johnstone A, Dunlop C, Heller R. Effect of contraception provided at termination of pregnancy and incidence of subsequent termination of pregnancy. *BJOG* 2012;119:1074–80. doi: 10.1111/j.1471-0528.2012.03407.x
36. Cremer M, Bullard KA, Mosley RM, Weisberg C, Molaei M, Lerner V, et al. Immediate vs. delayed post-abortion copper



- T 380A IUD insertion in cases over 12 weeks of gestation. *Contraception* 2011;83:522–7. doi: 10.1016/j.contraception.2010.10.005
37. Hohmann HL, Reeves MF, Chen BA, Perriera LK, Hayes JL, Creinin MD. Immediate versus delayed insertion of the levonorgestrel-releasing intrauterine device following dilation and evacuation: a randomized controlled trial. *Contraception* 2012;85:240–5. doi: 10.1016/j.contraception.2011.08.002
 38. Betstadt SJ, Turok DK, Kapp N, Feng KT, Borgatta L. Intrauterine device insertion after medical abortion. *Contraception* 2011;83:517–21. doi: 10.1016/j.contraception.2010.10.006
 39. Bednarek PH, Creinin MD, Reeves MF, Cwiak C, Espey E, Jensen JT. Post-aspiration IUD randomization (PAIR) study trial group. Immediate versus delayed IUD insertion after uterine aspiration. *N Engl J Med* 2011;364:2208–17. doi: 10.1056/NEJMoa1011600
 40. Eggebroten JL, Sanders JN, Turok DK. Immediate postpartum intrauterine device and implant program outcomes: a prospective analysis. *Am J Obstet Gynecol* 2017;217:51.e1–7. doi: 10.1016/j.ajog.2017.03.015
 41. Cohen R, Sheeder J, Arango N, Teal SB, Tocce K. Twelve-month contraceptive continuation and repeat pregnancy among young mothers choose postdelivery contraceptive implants or postplacental intrauterine devices. *Contraception* 2016;93:178–83. doi: 10.1016/j.contraception.2015.10.001
 42. Kapp N, Curtis K, Nanda K. Progestogen-only contraceptive use among breastfeeding women: a systematic review. *Contraception* 2010;82:17–37. doi: 10.1016/j.contraception.2010.02.002
 43. Turok DK, Leeman L, Sanders JN, Thaxton L, Eggebroten JL, Yonke N, et al. Immediate postpartum levonorgestrel intrauterine device insertion and breast-feeding outcomes: a non-inferiority randomized controlled trial. *Am J Obstet Gynecol* 2017;217:665.e1–8. doi: 10.1016/j.ajog.2017.08.003
 44. Levi EE, Findley MK, Avila K, Bryant AG. Placement of levonorgestrel intrauterine device at the time of cesarean delivery and the effect on breastfeeding duration. *Breastfeed Med* 2018;13:674–9. doi: 10.1089/bfm.2018.0060
 45. Carmo LSMP, Braga GC, Ferriani RA, Quintana SM, Vieira CS. Timing of etonogestrel-releasing implants and growth of breastfed infants: a randomized controlled trial. *Obstet Gynecol* 2017;130:100–7. doi: 10.1097/AOG.0000000000002092
 46. Braga GC, Ferrioli E, Quintana SM, Ferriani RA, Pfrimer K, Vieira CS. Immediate postpartum initiation of etonogestrel-releasing implant: a randomized controlled trial on breastfeeding impact. *Contraception* 2015;92:536–42. doi: 10.1016/j.contraception.2015.07.009
 47. Berry-Bibee EN, Tepper NK, Jatlaoui TC, Whiteman MK, Jamieson DJ, Curtis KM. The safety of intrauterine devices in breastfeeding women: a systematic review. *Contraception* 2016;94:725–38. doi: 10.1016/j.contraception.2016.07.006
 48. Averbach SH, Ermias Y, Jeng G, Curtis KM, Whiteman MK, Berry-Bibee E, et al. Expulsion of intrauterine devices after postpartum placement by timing of placement, delivery type, and intrauterine device type: a systematic review and meta-analysis. *Am J Obstet Gynecol* 2020;223:177–88. doi: 10.1016/j.ajog.2020.02.045
 49. Armstrong MA, Raine-Bennett T, Reed SD, Gatz J, Getahun D, Schoendorf J, et al. Association of the timing of postpartum intrauterine device insertion and breastfeeding with risks of intrauterine device expulsion. *JAMA Netw Open* 2022;5:e2148474. doi: 10.1001/jamanetworkopen.2021.48474
 50. Dewan R, Dewan A, Singal S, Bharti R, Kaim M. Non-visualisation of strings after postplacental insertion of Copper-T 380A intrauterine device. *J Fam Plann Reprod Health Care* 2017;43:186–94. doi: 10.1136/jfprhc-2015-101200
 51. Chen BA, Reeves MF, Hayes JL, Hohmann HL, Perriera LK, Creinin MD. Postplacental or delayed insertion of the levonorgestrel intrauterine device after vaginal delivery: a randomized controlled trial. *Obstet Gynecol* 2010;116:1079–87. doi: 10.1097/AOG.0b013e3181f73fac
 52. Whitaker AK, Endres LK, Mistretta SQ, Gilliam ML. Postplacental insertion of the levonorgestrel intrauterine device after cesarean delivery vs. delayed insertion: a randomized controlled trial. *Contraception* 2014;89:534–9. doi: 10.1016/j.contraception.2013.12.007
 53. Baldwin MK, Hart KD, Rodriguez MI. Predictors for follow-up among postpartum patients enrolled in a clinical trial. *Contraception* 2018;98:228–31. doi: 10.1016/j.contraception.2018.04.016
 54. Chen MJ, Hsia JK, Hou MY, Wilson MD, Creinin MD. Comparing postpartum visit attendance with a scheduled 2- to 3-week or 6-week visit after delivery. *Am J Perinatol* 2019;36:936–42. doi: 10.1055/s-0038-1675623
 55. Bellerose M, Collin L, Daw JR. The ACA Medicaid expansion and perinatal insurance, health care use, and health outcomes: a systematic review. *Health Aff (Millwood)* 2022;41:60–8. doi: 10.1377/hlthaff.2021.01150
 56. Mansour D, Mommers E, Teede H, Sollie-Eriksen B, Graesslin O, Ahrendt HJ, et al. Clinician satisfaction and insertion characteristics of a new applicator to insert radiopaque Implanon: an open-label, noncontrolled, multicenter trial. *Contraception* 2010;82:243–9. doi: 10.1016/j.contraception.2010.04.007
 57. Creinin MD, Kaunitz AM, Darney PD, Schwartz L, Hampton T, Gordon K, et al. The US etonogestrel implant mandatory clinical training and active monitoring programs: 6-year experience. *Contraception* 2017;95:205–10. doi: 10.1016/j.contraception.2016.07.012
 58. Reed S, Do Minh T, Lange JA, Koro C, Fox M, Heinemann K. Real world data on Nexplanon® procedure-related events: final results from the Nexplanon Observational Risk Assessment study (NORA). *Contraception* 2019;100:31–6. doi: 10.1016/j.contraception.2019.03.052
 59. Iwanaga J, Fox MC, Rekers H, Schwartz L, Tubbs RS. Neurovascular anatomy of the adult female medial arm in relationship to potential sites for insertion of the etonogestrel contraceptive implant. *Contraception* 2019;100:26–30. doi: 10.1016/j.contraception.2019.02.007
 60. Akdemir Y, Karadeniz M. The relationship between pain at IUD insertion and negative perceptions, anxiety and previous mode of delivery. *Eur J Contracept Reprod Health Care* 2019;24:240–5. doi: 10.1080/13625187.2019.1610872
 61. Lopez LM, Bernholz A, Zeng Y, Allen RH, Bartz D, O'Brien PA, et al. Interventions for pain with intrauterine device insertion. *The Cochrane Database of Systematic Reviews* 2015, Issue 7. Art. No.: CD007373. doi: 10.1002/14651858.CD007373.pub3
 62. Akers AY, Steinway C, Sonalkar S, Perriera LK, Schreiber C, Harding J, et al. Reducing pain during intrauterine device insertion: a randomized controlled trial in adolescents and young women. *Obstet Gynecol* 2017;130:795–802. doi: 10.1097/AOG.0000000000002242
 63. Mody SK, Farala JP, Jimenez B, Nishikawa M, Ngo LL. Paracervical block for intrauterine device placement among nulliparous women: a randomized controlled trial. *Obstet Gynecol* 2018;132:575–82. doi: 10.1097/AOG.0000000000002790



64. De Nadai MN, Poli-Neto OB, Franceschini SA, Yamaguti EMM, Monteiro IMU, Troncon JK, et al. Intrauterine block for levonorgestrel-releasing intrauterine system placement among nulligravid women: a randomized double-blind controlled trial. *Am J Obstet Gynecol* 2020;222:245.e1–10. doi: 10.1016/j.ajog.2019.09.013
65. Creinin MD, Schreiber C, Turok D, Cwiak C, Chen BA, Olariu AI. Levonorgestrel 52 mg intrauterine system efficacy and safety through 8 years of use. *Am J Obstet Gynecol* 2022 May 13 [epub ahead of print]. doi: 10.1016/j.ajog.2022.05.022
66. Barnett C, Moehner S, Do Minh T, Heinemann K. Perforation risk and intra-uterine devices: results of the EURAS-IUD 5-year extension study. *Eur J Contracept Reprod Health Care* 2017;22:424–8. doi: 10.1080/13625187.2017.1412427
67. Rowlands S, Oloto E, Horwell DH. Intrauterine devices and risk of uterine perforation: current perspectives. *Open Access J Contracept* 2016;7:19–32. doi: 10.2147/OAJC.S85546
68. Sufirin CB, Postlethwaite D, Armstrong MA, Merchant M, Wendt JM, Steinauer JE. Neisseria gonorrhoea and Chlamydia trachomatis screening at intrauterine device insertion and pelvic inflammatory disease. *Obstet Gynecol* 2012;120:1314–21. doi: 10.1097/aog.0b013e318273364c
69. Turok DK, Eisenberg DL, Teal SB, Keder LM, Creinin MD. A prospective assessment of pelvic infection risk following same-day sexually transmitted infection testing and levonorgestrel intrauterine system placement. *Am J Obstet Gynecol* 2016;215:599.e1–6. doi: 10.1016/j.ajog.2016.05.017
70. Andersson K, Odland V, Rybo G. Levonorgestrel-releasing and copper-releasing (Nova T) IUDs during five years of use: a randomized comparative trial. *Contraception* 1994;49:56–72. doi: 10.1016/0010-7824(94)90109-0
71. Pymar HC, Creinin MD, Schwartz JL. Pop-out" method of levonorgestrel implant removal. *Contraception* 1999;59:383–7. doi: 10.1016/s0010-7824(99)00048-7
72. Kwal J, Maguire K, Carugno J. Localization and management of nonpalpable radiopaque contraceptive implant. *Contraception* 2022;106:3–5. doi: 10.1016/j.contraception.2021.10.002
73. Mastey N, Matulich MC, Uhm S, Baker CC, Melo J, Chen MJ, et al. US referral center experience removing nonpalpable and difficult contraceptive implants with in-office ultrasonography: a case series. *Contraception* 2021;103:428–30. doi: 10.1016/j.contraception.2021.01.018
74. Matulich MC, Chen MJ, Schimmoeller NR, Hsia JK, Uhm S, Wilson MD, et al. Referral center experience with nonpalpable contraceptive implant removals. *Obstet Gynecol* 2019;134:801–6. doi: 10.1097/AOG.0000000000003457
75. Petro G, Spence T, Patel M, Gertz AM, Morroni C. Difficult etonogestrel implant removals in South Africa: a review of 74 referred cases. *Contraception* 2020;102:129–32. doi: 10.1016/j.contraception.2020.04.013
76. Faúndes D, Bahamondes L, Faúndes A, Petta CA. T-shaped IUD move vertically with endometrial growth and involution during the menstrual cycle. *Contraception* 1998;57:413–5. doi: 10.1016/s0010-7824(98)00049-3
77. Morales-Roselló J. Spontaneous upward movement of lowly placed T-shaped IUDs. *Contraception* 2005;72:430–1. doi: 10.1016/j.contraception.2005.06.064
78. Bounds W, Hutt S, Kubba A, Cooper K, Guillebaud J, Newman GB. Randomised comparative study in 217 women of three disposable plastic IUCD thread retrievers. *Br J Obstet Gynaecol* 1992;99:915–9. doi: 10.1111/j.1471-0528.1992.tb14442.x
79. Swenson C, Royer PA, Turok DK, Jacobson JC, Amaral G, Sanders JN. Removal of the LNG IUD when strings are not visible: a case series. *Contraception* 2014;90:288–90. doi: 10.1016/j.contraception.2014.04.007
80. Moro F, Knez J, Pateman K, Derdelis G, Foo X, Jurkovic D. Ultrasound-guided retrieval of lost intrauterine devices using very fine grasping forceps: a case series. *J Fam Plann Reprod Health Care* 2015;41:205–9. doi: 10.1136/jfprhc-2014-101088
81. Verma U, Astudillo-Dávalos FE, Gerkowicz SA. Safe and cost-effective ultrasound guided removal of retained intrauterine device: our experience. *Contraception* 2015;92:77–80. doi: 10.1016/j.contraception.2015.02.008
82. Mizia K, Ramsay P. The effectiveness and safety of ultrasound-guided removal of a Mirena® intrauterine system when the strings are not visible and conventional office procedures have failed. *Aust N Z J Obstet Gynaecol* 2013;53:386–8. doi: 10.1111/ajo.12103
83. Kasuga Y, Lin BL, Maki J, Wang H, Yoshimura T, Nagai Y, et al. Twelve-year experience of office-setting removal of lost intrauterine devices in place for more than 10 years. *Eur J Contracept Reprod Health Care* 2019;24:206–8. doi: 10.1080/13625187.2019.1602763
84. Jain A, Singh S, Elliyas S. Effectiveness of manual vacuum aspiration (MVA) device in the management of intrauterine copper devices (IUCD) with missing strings: a prospective interventional study. *J Obstet Gynaecol India* 2021;71:424–9. doi: 10.1007/s13224-021-01440-x
85. Turok DK, Gurtcheff SE, Gibson K, Handley E, Simonsen S, Murphy PA. Operative management of intrauterine device complications: a case series report. *Contraception* 2010;82:354–7. doi: 10.1016/j.contraception.2010.04.152
86. Wilson S, Tan G, Baylson M, Schreiber C. Controversies in family planning: how to manage a fractured IUD. *Contraception* 2013;88:599–603. doi: 10.1016/j.contraception.2013.07.007
87. Brahm D, Steenland MW, Renner RM, Gaffield ME, Curtis KM. Pregnancy outcomes with an IUD in situ: a systematic review. *Contraception* 2012;85:131–9. doi: 10.1016/j.contraception.2011.06.010
88. Ozgu-Erdinc AS, Tasdemir UG, Uygur D, Aktulay A, Tasdemir N, Gulerman HC. Outcome of intrauterine pregnancies with intrauterine device in place and effects of device location on prognosis. *Contraception* 2014;89:426–30. doi: 10.1016/j.contraception.2014.01.002
89. Schiesser M, Lapaire O, Tercanli S, Holzgreve W. Lost intrauterine devices during pregnancy: maternal and fetal outcome after ultrasound-guided extraction. An analysis of 82 cases. *Ultrasound Obstet Gynecol* 2004;23:486–9. doi: 10.1002/uog.1036
90. O'Connor KA, Ferrell R, Brindle E, Trumble B, Shofer J, Holman DJ, et al. Progesterone and ovulation across stages of the transition to menopause. *Menopause* 2009;16:1178–87. doi: 10.1097/gme.0b013e3181aa192d
91. Gebbie AE, Glasier A, Sweeting V. Incidence of ovulation in perimenopausal women before and during hormone replacement therapy. *Contraception* 1995;52:221–2. doi: 10.1016/0010-7824(95)00184-c
92. Andersson K, Mattsson LA, Rybo G, Stadberg E. Intrauterine release of levonorgestrel—a new way of adding progestogen in hormone replacement therapy. *Obstet Gynecol* 1992;79:963–7.
93. Depypere HT, Hillard T, Erkkola R, Lukkari-Lax E, Kunz M, Rautiainen P, et al. A 60-month non-comparative study on bleeding profiles with the levonorgestrel intrauterine system from the late transition period to estrogen supplemented menopause. *Eur J Obstet Gynecol Reprod Biol* 2010;153:176–80. doi: 10.1016/j.ejogrb.2010.08.017



94. Boon J, Scholten PC, Oldenhove A, Heintz AP. Continuous intrauterine compared with cyclic oral progestin administration in perimenopausal HRT. *Maturitas* 2003;46:69–77. doi: 10.1016/s0378-5122(03)00163-4
95. Sitruk-Ware R. The levonorgestrel intrauterine system for use in peri- and postmenopausal women. *Contraception* 2007;75:S155–60. doi: 10.1016/j.contraception.2007.01.010
96. Wu S, Godfrey EM, Wojdyla D, Dong J, Cong J, Wang C, et al. Copper T380A intrauterine device for emergency contraception: a prospective, multicentre, cohort clinical trial. *BJOG* 2010;117:1205–10. doi: 10.1111/j.1471-0528.2010.02652.x
97. Thompson I, Sanders JN, Schwarz EB, Boraas C, Turok DK. Copper intrauterine device placement 6–14 days after unprotected sex. *Contraception* 2019;100:219–21. doi: 10.1016/j.contraception.2019.05.015
98. Peipert JF, Zhao Q, Allsworth JE, Petrosky E, Madden T, Eisenberg D, et al. Continuation and satisfaction of reversible contraception. *Obstet Gynecol* 2011;117:1105–13. doi: 10.1097/AOG.0b013e31821188ad
99. Turok DK, Gero A, Simmons RG, Kaiser JE, Stoddard GJ, Sexsmith CD, et al. Levonorgestrel vs. copper intrauterine devices for emergency contraception. *N Engl J Med* 2021;384:335–44. doi: 10.1056/NEJMoa2022141
100. Fay KE, Clement AC, Gero A, Kaiser JE, Sanders JN, BakenRa AA, et al. Rates of pregnancy among levonorgestrel and copper intrauterine emergency contraception initiators: implications for backup contraception recommendations. *Contraception* 2021;104:561–6. doi: 10.1016/j.contraception.2021.06.011
101. BakenRa A, Gero A, Sanders J, Simmons R, Fay K, Turok DK. Pregnancy risk by frequency and timing of unprotected intercourse before intrauterine device placement for emergency contraception. *Obstet Gynecol* 2021;138:79–84. doi: 10.1097/AOG.0000000000004433
102. Dinh A, Sriprasert I, Williams AR, Archer DF. A review of the endometrial histologic effects of progestins and progesterone receptor modulators in reproductive age women. *Contraception* 2015;91:360–7. doi: 10.1016/j.contraception.2015.01.008
103. Funk S, Miller MM, Mishell DR Jr, Archer DF, Poindexter A, Schmidt J, et al. Safety and efficacy of Implanon, a single-rod implantable contraceptive containing etonogestrel. *Contraception* 2005;71:319–26. doi: 10.1016/j.contraception.2004.11.007
104. Diedrich JT, Zhao Q, Madden T, Secura GM, Peipert JF. Three-year continuation of reversible contraception. *Am J Obstet Gynecol* 2015;213:662.e1–8. doi: 10.1016/j.ajog.2015.08.001
105. Mansour D, Korver T, Marintcheva-Petrova M, Fraser IS. The effects of Implanon on menstrual bleeding patterns. *Eur J Contracept Reprod Health Care* 2008;13:13–28. doi: 10.1080/13625180801959931
106. Mansour D, Fraser IS, Edelman A, Vieira CS, Kaunitz AM, Korver T, et al. Can initial vaginal bleeding patterns in etonogestrel implant users predict subsequent bleeding in the first 2 years of use? *Contraception* 2019;100:264–8. doi: 10.1016/j.contraception.2019.05.017
107. Mansour D, Bahamondes L, Critchley H, Darney P, Fraser IS. The management of unacceptable bleeding patterns in etonogestrel-releasing contraceptive implant users. *Contraception* 2011;83:202–10. doi: 10.1016/j.contraception.2010.08.001
108. Henkel A, Goldthwaite LM. Management of bothersome bleeding associated with progestin-based long-acting reversible contraception: a review. *Curr Opin Obstet Gynecol* 2020;32:408–15. doi: 10.1097/GCO.0000000000000664
109. Hou MY, McNicholas C, Creinin MD. Combined oral contraceptive treatment for bleeding complaints with the etonogestrel contraceptive implant: a randomised controlled trial. *Eur J Contracept Reprod Health Care* 2016;21:361–6. doi: 10.1080/13625187.2016.1210122
110. Guaihi M, McBride M, Sheeder J, Teal S. Short-term treatment of bothersome bleeding for etonogestrel implant users using a 14-day oral contraceptive pill regimen: a randomized controlled trial. *Obstet Gynecol* 2015;126:508–13. doi: 10.1097/AOG.0000000000000974
111. Chen MJ, Hsia JK, Creinin MD. Etonogestrel implant use in women primarily choosing a combined oral contraceptive pill: a proof-of-concept trial. *Contraception* 2018;97:533–7. doi: 10.1016/j.contraception.2018.02.009
112. Hubacher D, Chen PL, Park S. Side effects from the copper IUD: do they decrease over time? *Contraception* 2009;79:356–62. doi: 10.1016/j.contraception.2008.11.012
113. Rowe P, Farley T, Peregoudov A, Piaggio G, Boccard S, Landoulsi S, et al. IUD research group of the UNDP/UNFPA/WHO/world bank special programme of research; development and research training in human reproduction. Safety and efficacy in parous women of a 52-mg levonorgestrel-medicated intrauterine device: a 7-year randomized comparative study with the TCu380A. *Contraception* 2016;93:498–506. doi: 10.1016/j.contraception.2016.02.024
114. Teal SB, Turok DK, Chen BA, Kimble T, Olariu AI, Creinin MD. Five-year contraceptive efficacy and safety of a levonorgestrel 52-mg intrauterine system. *Obstet Gynecol* 2019;133:63–70. doi: 10.1097/AOG.0000000000003034
115. Goldthwaite LM, Creinin MD. Comparing bleeding patterns for the levonorgestrel 52 mg, 19.5 mg, and 13.5 mg intrauterine systems. *Contraception* 2019;100:128–31. doi: 10.1016/j.contraception.2019.03.044
116. Grimes DA, Lopez LM, Manion C, Schulz KF. Cochrane systematic reviews of IUD trials: lessons learned. *Contraception* 2007;75:S55–9. doi: 10.1016/j.contraception.2006.12.004
117. Imai A, Matsunami K, Takagi H, Ichigo S. Levonorgestrel-releasing intrauterine device used for dysmenorrhea: five-year literature review. *Clin Exp Obstet Gynecol* 2014;41:495–8.
118. Gibbons T, Georgiou EX, Cheong YC, Wise MR. Levonorgestrel-releasing intrauterine device (LNG-IUD) for symptomatic endometriosis following surgery. *The Cochrane Database of Systematic Reviews* 2021, Issue 12. Art. No.: CD005072. doi: 10.1002/14651858.CD005072.pub4
119. Soysal S, Soysal ME. The efficacy of levonorgestrel-releasing intrauterine device in selected cases of myoma-related menorrhagia: a prospective controlled trial. *Gynecol Obstet Invest* 2005;59:29–35. doi: 10.1159/000080932
120. Cho S, Nam A, Kim H, Chay D, Park K, Cho DJ, et al. Clinical effects of the levonorgestrel-releasing intrauterine device in patients with adenomyosis. *Am J Obstet Gynecol* 2008;198:373.e1–7. doi: 10.1016/j.ajog.2007.10.798
121. Kingman CE, Kadir RA, Lee CA, Economides DL. The use of levonorgestrel-releasing intrauterine system for treatment of menorrhagia in women with inherited bleeding disorders. *BJOG* 2004;111:1425–8. doi: 10.1111/j.1471-0528.2004.00305.x
122. Pisoni CN, Cuadrado MJ, Khamashta MA, Hunt BJ. Treatment of menorrhagia associated with oral anticoagulation: efficacy and safety of the levonorgestrel releasing intrauterine device (Mirena coil). *Lupus* 2006;15:877–80. doi: 10.1177/0961203306071706



123. Pal N, Broaddus RR, Urbauer DL, Balakrishnan N, Milbourne A, Schmeler KM, et al. Treatment of low-risk endometrial cancer and complex atypical hyperplasia with the levonorgestrel-releasing intrauterine device. *Obstet Gynecol* 2018;131:109–16. doi: 10.1097/AOG.0000000000002390
124. U.S. Food and Drug Administration. “Off-label” and investigational use of marketed drugs, biologics, and medical devices: guidance for institutional review boards and clinical investigators. Accessed March 6, 2022. <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/label-and-investigational-use-marketed-drugs-biologics-and-medical-devices>
125. Ali M, Akin A, Bahamondes L, Brache V, Habib N, Landoulsi S, et al WHO study group on subdermal contraceptive implants for women. Extended use up to 5 years of the etonogestrel-releasing subdermal contraceptive implant: comparison to levonorgestrel-releasing subdermal implant. *Hum Reprod* 2016;31:2491–8. doi: 10.1093/humrep/dew222
126. McNicholas C, Swor E, Wan L, Peipert JF. Prolonged use of the etonogestrel implant and levonorgestrel intrauterine device: 2 years beyond Food and Drug Administration-approved duration. *Am J Obstet Gynecol* 2017;216:586.e1–6. doi: 10.1016/j.ajog.2017.01.036
127. World Health Organization. Long-term reversible contraception. Twelve years of experience with the TCu380A and TCu220C. *Contraception* 1997;56:341–52.
128. Sivin I. Utility and drawbacks of continuous use of a copper T IUD for 20 years. *Contraception* 2007;75:S70–5. doi: 10.1016/j.contraception.2007.01.016
129. Bahamondes L, Faundes A, Sobreira-Lima B, Lui-Filho JF, Pecci P, Matera S. TCu 380A IUD: a reversible permanent contraceptive method in women over 35 years of age. *Contraception* 2005;72:337–41. doi: 10.1016/j.contraception.2004.12.026
130. Creinin MD, Jansen R, Starr RM, Gobburu J, Gopalakrishnan M, Olariu A. Levonorgestrel release rates over 5 years with the Liletta® 52-mg intrauterine system. *Contraception* 2016;94:353–6. doi: 10.1016/j.contraception.2016.04.010
131. Schreiber CA, Madden T. Complex family planning: a newly accredited, landmark fellowship. *Contraception* 2021;103:1–2. doi: 10.1016/j.contraception.2020.10.002

PEER REVIEW HISTORY

Received March 21, 2022. Received in revised form June 7, 2022. Accepted June 9, 2022. Peer reviews and author correspondence are available at <http://links.lww.com/AOG/C892>.

CME FOR THE CLINICAL EXPERT SERIES

Learning Objectives for “Long-Acting Reversible Contraception”

After completing this continuing education activity, you will be able to:

- Discuss the currently available long-acting reversible contraceptive options;
- Review the nomenclature of long-acting reversible contraceptives;
- Outline the role of long-acting reversible contraceptives in the framework of bodily autonomy and reproductive justice; and
- Implement a practice environment employing long-acting reversible contraceptives for appropriate patients.

Instructions for Obtaining AMA PRA Category 1 Credits™

Continuing Medical Education credit is provided through joint providership with The American College of Obstetricians and Gynecologists.

Obstetrics & Gynecology includes CME-certified content that is designed to meet the educational needs of its readers. This article is certified for 2 AMA PRA Category 1 Credits.™ This activity is available for credit through November 30, 2025.

Accreditation Statement

ACCME Accreditation

The American College of Obstetricians and Gynecologists is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AMA PRA Category 1 Credit(s)™

The American College of Obstetricians and Gynecologists designates this **journal-based CME activity** for a maximum of 2 AMA PRA Category 1 Credits.™ Physicians should claim only the credit commensurate with the extent of their participation in the activity.

College Cognate Credit(s)

The American College of Obstetricians and Gynecologists designates this **journal-based CME activity** for a maximum of 2 Category 1 College Cognate Credits. The College has a reciprocity agreement with the AMA that allows *AMA PRA Category 1 Credits*™ to be equivalent to College Cognate Credits.

Disclosure of Faculty and Planning Committee

Industry Relationships

In accordance with the College policy, all faculty and planning committee members have signed a conflict of interest statement in which they have disclosed any financial interests or other relationships with industry relative to article topics. Such disclosures allow the participant to evaluate better the objectivity of the information presented in the articles.

How to Earn CME Credit

To earn CME credit, you must read the article in *Obstetrics & Gynecology* and complete the quiz, answering at least 70 percent of the questions correctly. For more information on this CME educational offering, visit the Lippincott CMEConnection portal at <https://cme.lww.com/browse/sources/196> to register and to complete the CME activity online. ACOG Fellows will receive 50% off by using coupon code, **ONG50**.

Hardware/software requirements are a desktop or laptop computer (Mac or PC) and an Internet browser. This activity is available for credit through November 30, 2025. To receive proper credits for this activity, each participant will need to make sure that the information on their profile for the CME platform (where this activity is located) is updated with 1) their date of birth (month and day only) and 2) their ACOG ID. In addition, participants should select that they are board-certified in obstetrics and gynecology.

The privacy policies for the *Obstetrics & Gynecology* website and the Lippincott CMEConnection portal are available at <http://www.greenjournal.org> and <https://cme.lww.com/browse/sources/196>, respectively.

Contact Information

Questions related to transcripts may be directed to cme@acog.org. For other queries, please contact the *Obstetrics & Gynecology* Editorial Office at obgyn@greenjournal.org. For queries related to the CME test online, please contact ceconnection@wolterskluwer.com or 1-800-787-8985.

